Objects: Researching on the relationship between serum levels of CA-125 in FIGO stage IIIC ovarian carcinoma patients before and after treatment with their survival. Subjects. 82 patients with stage mc ovarian carcinoma were treated with maximum debuking surgery and adjuvant paclitaxel/carboplatin regimens, from 11-2005 to 11-2010 at K hospital. Results: Before treatment, the patient's average CA125 levels was 407.1 + or - 660.7 U/ml. The 24 months survival rate of patients with CA-125 300U/ml was 53.1 percent that was higher than patients with CA-125 300U/ml (35 percent). The media survival of patients with CA-125 300U/ml was 18.9 percent higher than the patients with CA-125 300 U/ml (16.7 months) (p 0.05). After treatment, the 24 months survival rate of patients with CA-125 levels : or 35U/ml (16.7 percent). The media survival of patients with CA-125 or 35U/ml (15.8 months) (p 0.05). Recurrence risk of patients with CA-125 35U/ml was 3.8 times higher than patients with CA-125 or